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Abstract 
Current evidence recommends and supports deprescribing medications to reduce 
polypharmacy in the hospice population. The project aim was to determine accurate percentages 
of deprescribing at three-time periods: before hospice admission, at hospice enrollment, and four 
weeks post hospice enrollment. This project was a retrospective review of the medication 
administration record (MAR) of patients admitted into Sharp Hospice from a Sharp Healthcare 
facility. Sharp Hospice, in California, USA, admitted 164 patients during August 2020. Of those, 
34 patients were eligible for inclusion in this retrospective quality improvement review. Prior to 
discharge from at a Sharp facility, the percentage of target medications on the inpatient 
medication record equaled 80.5% for antihypertensives, 61.1% for statins, and 22.2% for oral 
diabetic medications for the sample. At hospice admission, 61.0 % of these patients were 
appropriately deprescribed, 13.8 % of patients were partially deprescribed, meaning some 
eligible medications were removed, and 25% of patients were not deprescribed. 64 % of patients 
were appropriately deprescribed target medications during the first four weeks of hospice 
enrollment. The results confirmed medication deprescribing is occurring but also identified 
missed opportunities for deprescribing in Sharp Hospice. These conclusions are beneficial and 
applicable to the next phase of project implementation to improve the organization's 
deprescribing percentages. 
 
Keywords: Polypharmacy, deprescribing, hospice, end of life 
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Deprescribing in the Hospice Population, Who is Eligible and Who is Agreeable: A Quality 
Improvement Project  
Background and Significance: Polypharmacy and Deprescribing in Hospice 
Hospice clinicians are challenged with tertiary prevention of many complex and end-
stage disease processes, which have resulted in a laundry list of medications. Successful 
management of the hospice patient includes careful consideration of each medication previously 
prescribed to determine if it is necessary for the current goals of care, emphasizing symptom 
relief. Polypharmacy, defined as more medications than medically necessary, is not confined to 
the elderly, but they are most at risk of potentially inappropriate medications (PIMs) (Masnoon, 
2017). Deprescribing is a term used to eliminate medications after a careful risk versus benefit 
analysis for each patient (Thompson, 2019). Often, treatment of comorbid conditions results in a 
prescribing cascade, leading to multiple additional medications. Although medical providers are 
taught about medication side effects throughout their education, associating polypharmacy with 
clinical symptoms is not always high on the differential diagnosis list. Research has suggested 
29-51% of preventive medications such as aspirin, anti-hypertensives, and statins are continued 
in patients with a limited life expectancy, even though the timeframe of any potential benefits for 
these medications may be far longer than a patient's expected survival (Pruskowski, 2016). 
Deprescribing may be underutilized for hospice patients which can result in unmet goals of care, 
specifically the reduction pain and suffering at the end of life. It is imperative to bridge the gap 
regarding the benefits of deprescribing and the reduction of polypharmacy to hospice patients 
and their families and promote a routine deprescribing plan within hospices.  
The idea began in 2019 after sitting in on several weekly interdisciplinary team meetings 
in Sharp Hospice. This team included a member from each service in the hospice agency, 
4 
 
including the clinical pharmacist, nurse practitioners, physicians, social workers, nurses, and 
chaplains. During this time, the team completed an individual chart review for each patient and 
discussed medications exhaustively, determining to continue to or to deprescribe. Often, this 
process was not time-efficient and resulted in miscommunication between clinicians, outlining 
the scope of the problem. The project goal was to determine how efficient current deprescribing 
practice was by assessing the percentage of target medication deprescribed at different time 
intervals. Target medications were identified during the interdisciplinary team meetings for 
inclusion and finalized after a literature review and synthesis of the evidence. The identified 
outcome was deprescribing being completed on patients, yet with a realization there was no 
standardized process which could result in some missed opportunities. 
Evidence for the Project  
Polypharmacy is a substantial problem in the elderly population and specifically with 
hospice patients. Deprescribing of certain medications during the end of life period is beneficial 
and appropriate for this patient population which has been demonstrated as level one evidence 
according to the Johns Hopkins Model (Cooper et.al., 2015). There is a multitude of additional 
level two and three evidence concluding deprescribing with a limited life expectancy is not only 
beneficial but reduces the risk of harm (Chau, et al., 2016; Schnecker et al., 2019). The following 
databases were searched for evidence: CINAHL, PubMed, EBSCOhost. Terms searched 
included: “Deprescribing AND Hospice,” “Deprescribing AND Hypertensive Medications,” 
“Deprescribing AND Statins,” Deprescribing AND Aspirin,” “Deprescribing AND 
Hypoglycemics,” “Deprescribing AND Cost Reduction,” “Deprescribing AND Polypharmacy”, 
“Deprescribing AND Geriatrics”, “Polypharmacy AND Hospice”. After completing a literature 
review to acquire the current evidence, the scope of the problem was better understood. 
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Metabolic Changes with Aging  
As the body ages, the pharmacokinetics of drug absorption, metabolism, and excretion 
becomes impaired, which translates to a need for a reduced dose to achieve the medication’s 
same effect. The gastrointestinal system’s ability to absorb changes with age and multiple 
medications cause alterations in absorption bioavailability, inducing the effects of polypharmacy. 
Due to inadequate water, fat, and protein concentrations in malnourished and dehydrated hospice 
patients, drug distribution is affected, and there is a greater risk of developing toxicity (Malone, 
2019). Drug metabolism, which occurs primarily in the liver’s cytochrome P (CYP) system, is 
also reduced. Elimination of drugs is most affected by the natural pharmacokinetic changes 
associated with age. Renal function declines steadily as aging occurs, even in the absence of 
disease, creating an extended half-life, allowing the drug to remain bioavailable in the body 
(Malone, 2019). For example, as renal function declines and drug excretion is prolonged, the 
half-life of glipizide medications, specifically Metformin, increases leading to a higher 
occurrence of hypoglycemia. (American Diabetic Association, 2021; Jeffreys, 2015). These 
pharmacokinetic and physiological changes have significant importance in a deprescribing 
discussion in the hospice population as the mean age of patients included in this analysis was 76 
years old. 
Concurrently with advancing age, the number of medications prescribed increases due to 
worsening of existing conditions and new disease processes. This combination of taking multiple 
medications and pharmacokinetics changes creates an environment for increased risk of adverse 
drug events, morbidity, and mortality. According to a population-based study, the average 
number of medications prescribed to an elderly patient over the age of 65 is more than five 
medications, and the risk of an adverse drug event is over 88% (Chau et al., 2016). Many elderly 
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patients are at higher risk of an adverse drug reaction, and clinicians should take a standardized 
approach to reduce polypharmacy. Another specific example of polypharmacy leading to drug-
drug interaction is concurrent use of diabetic agents and aspirin, which can inhibit desired 
hypoglycemia (Frechen et al., 2012). Polypharmacy is inevitable in the elderly population and 
increased in the hospice population without a comprehensive medication review and 
discontinuation plan. 
Deprescribing Target Medications  
Understanding which medications are appropriate to deprescribe requires evaluating the 
expected life span remaining, risk of an adverse event outweighing the benefits, and the current 
goals of care (Bukowy & Teso, n.d.). Deprescribing medications is an essential aspect of care for 
all patients, but there is an increased emphasis on patients enrolled in hospice services as the 
medication’s time to benefit may be greater than life expectancy. The topic of deprescribing may 
seem straightforward to many advanced clinicians, yet the simple act of discontinuing 
medications may present difficulties to patients and their families. A common misunderstanding 
due to lack of education could occur, as they may perceive deprescribing in hospice as hastening 
a loved one’s death. This complicated emotional and psychological time during the end of life 
presents unique challenges when providing education. As end-of-life approaches, most of the 
patient’s medications are not valuable or relevant to the current goals of care and may cause 
unwanted side effects and drug-drug interactions. Although the evidence supports routine 
deprescribing in the hospice population, it is essential to provide patients and families with 
education regarding the benefits. This retrospective analysis of deprescribing rates in Sharp 
Hospice is designed to prepare for phased implementation and assessment of barriers hindering 
education and implementation, as the next feasible step is to remove such barriers. 
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A retrospective study evaluated the current prescribing and deprescribing practices for 
patients with palliative care services (McLean et al., 2013). The study reviewed prescribed 
medications to treat the most common comorbidities such as cardiovascular disease, ischemic 
heart disease, and dyslipidemia. According to the investigators, the number of medications 
during the last few weeks of life increased dramatically, with a mean total of 10 medications in 
the last week of life. Yet, there was little documentation found regarding deprescribing during 
this time. The authors also noted limited evidence regarding the burden of polypharmacy at the 
end of life. However, there is significant evidence supporting the benefits of deprescribing at the 
end of life, and there is a need for a standardized guideline to streamline the process and 
effectively deprescribe.   
According to Kutner, et al. (2015), in a randomized controlled clinical trial (RCT) of end-
of-life patients and discontinuing statin therapy, removing the statin was safe and beneficial in 
terms of quality of life and reduced pill burden. This study resulted in a reduction of multiple 
complaints in the group who discontinued the statin. The symptoms, including muscle spasms, 
reduced strength, and exercise intolerance, were decreased in the arm of patients who 
discontinued statin therapy as compared to the group that continued therapy. One of the 
significant driving factors, which evidence has found to be valid and reliable, is the changes in 
pharmacokinetics, specifically metabolism, limiting the full potential benefit of statin therapy. 
Discussion with the patient and their families regarding the benefit versus burden of statin 
therapy with a decreased survival time included information that continued use would not result 
in a better outcome. However, informing patients and families of the physiologic benefits may 
not be convincing enough for the patient to agree to deprescribing. Explaining that a reduction in 
pill burden with no apparent harmful effects on life expectancy and reduced monthly costs could 
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help persuade the patient to agree to eliminate statin therapy. Another RCT including 381 
patients with limited life expectancy concluded no difference in 60-day mortality or 
cardiovascular events in one month to one year with statin discontinuation (Bukowy & Teso, 
n.d.). Other beneficial aspects found were the improved quality of life for the hospice patient and 
reduced medication cost for the group who had medications discontinued as compared to the 
group who continued statin therapy.  
Diabetes management for patients with a limited prognosis is not the same treatment plan 
for patients with an expected lifespan of many years. According to the American Diabetes 
Association, the Type 2 diabetic hospice patient should have a management goal of reducing the 
incidence of hypoglycemia and symptomatic hyperglycemia (2021). Once end-organ damage 
occurs, multiple agents will require a dose reduction or elimination to prevent polypharmacy and 
adverse drug reactions (American Diabetes Association, 2021). The Canadian Deprescribing 
Network has developed several research-based guidelines detailing how to achieve successful 
and safe deprescribing of anti-hyperglycemic agents, which are beneficial for applying in the 
clinical practice (Deprescribing Network, 2020). In a Cochrane meta-analysis review of 
interventions to reduce polypharmacy in the elderly, 12 studies were reviewed, concluding there 
is a lack of interventional research to improve polypharmacy (Cooper et al., 2015). Stopping 
diabetic medications in patients with an anticipated survival of weeks was deemed safe to 
prevent a hypoglycemic event with the rapid oral intake reduction. Although hyperglycemia may 
occur, it is unlikely the Type 2 diabetic hospice patient will go into a hyperosmolar 
hyperglycemic state due to the erratic eating patterns during end-of-life. Discussion with families 
and patients that tight glycemic control is not appropriate during the end-of-life period as the 
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goal is not to prevent the long-term complications of diabetes (secondary prevention) but to 
avoid hypoglycemia (Jeffreys et al., 2015). 
Similar to abandoning strict blood glucose control, loosening blood pressure control with 
the hospice patient is safe. The goal for blood pressure should be less than 180/90 as 
symptomatic hypertension is associated with increases above this number. In most cases, it is 
safe to deprescribe anti-hypertensives to prevent the occurrence of hypotension, which is a 
higher risk at the end-of-life and can result in unintended adverse events, including dizziness and 
falls. Although, as an exception, discontinuing beta blockers is not appropriate as the aim to 
directed at heart rate rather than blood pressure management. In the hospice population, primary 
prevention of disease processes is not the goal, and for anti-hypertensives, the time to therapeutic 
benefit is longer than life expectancy (Thompson, 2019). In a parallel-group, unblinded clinical 
trial, anti-hypertensive medications were deprescribed in an older adult population having 
advanced disease. Concluding after the 16-week follow-up visit, there were no increased adverse 
events, although systolic blood pressure was elevated by a mean increase of 7.36 mm Hg and 
diastolic blood pressure elevated by a mean increase of 2.63 mm Hg (Moonen et al., 2015). 
Conclusions from Moonen’s study, along with numerous others, indicated that appropriate 
discontinuing of anti-hypertensives can alleviate polypharmacy, pill burden, and adverse drug 
events in the patient with a limited prognosis. 
Aspirin as a primary prevention strategy to reduce cardiovascular disease has been 
controversial in the last few years for older adults. Historically, aspirin has been prescribed daily 
for 40-70 years old to reduce the 10-year risk of myocardial infarction or ischemic stroke. 
Nevertheless, with advanced age over 70 years old in conjunction with multiple comorbidities, 
aspirin’s continued use has been associated with significant bleeding risk (Selak et al., 2018). 
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Concerning hospice patients specifically, continued use of primary prevention aspirin is 
considered insignificant as the long-term efficacy exceeds the life expectancy. In 2019, the 
American College of Cardiology (ACC) updated its guidelines and revoked the previous 
recommendation to use aspirin as primary prevention. Modifying the guidelines for routine 
aspirin use in the elderly population has changed because of multiple RCTs, meta-analyses, and 
high-quality cohort studies (Jacobsen et al., 2020). Such evidence has determined continuing 
aspirin therapy is associated with major hemorrhagic events in the elderly and does not reduce 
cardiovascular mortality or morbidity (Arnett et al., 2019). 
Methods 
Designed as a phased retrospective quality improvement project, there is potential for 
implementing a streamlined and consistent method to improve deprescribing within Sharp 
Hospice. This project can expand into an interventional evidence-based practice project by 
implementing a deprescribing protocol and educational plan. This project can be sustained as 
standard practice throughout Sharp Hospice with increased awareness regarding how many 
patients are accurately being deprescribed. This project’s next crucial step will be providing 
education to the patients and families by assessing their baseline and willingness to learn more 
about how deprescribing and polypharmacy and clinician participation in routine deprescribing 
practices. Polypharmacy and deprescribing are new terms to many patients and their families, 
requiring extensive education to improve patient’s agreement with removing medications during 
hospice enrollment or soon after that. Conversations with patients and their families, not once but 
repeatedly during the hospice services, are vital to reducing polypharmacy burden without 
misinterpreting medications’ removal to hasten death. Once the education is delivered, 
deprescribing may be acknowledged as more helpful than harmful by patients and their families, 
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improving deprescribing rates. Patients and their families will conduct a pre-and post-
assessment, if cognitively intact and agreeable, determining if the education was impactful.  
After determining sufficient evidence and completing an appraisal, it was concluded that 
medications used for risk reduction in long-term medical management are appropriate to 
deprescribe in the end-of-life period (Copper 2015). The original PICOT question was: “In 
newly enrolled hospice patients (P), will eligibility screening for medication deprescribing (I) 
result in discontinuation of target medications (O) compared to usual care (C) over four weeks 
(T)?” Unfortunately, due to the COVID-19 pandemic, this PICOT question could not be entirely 
answered as the project design required modifications to adhere to isolation restrictions. It was 
decided to shift the project’s focus to an early phase, noninterventional quality improvement 
project at Sharp Hospice to screen patients to determine who was eligible for target medication 
deprescribing and capture data regarding current deprescribing practices. This necessary first 
step will provide accurate data to clinicians and administrators for deprescribing program 
planning in the subsequent phases of the project. After extensive literature review, the identified 
medications referred to as target medications in this project, can be deprescribed without 
increasing mortality (Deprescribing Network, 2020). Identified target medications included: 
antihypertensives, excluding medications for heart rate control, such as beta blockers, anti-
hyperlipidemics, and diabetic medications, excluding insulins. The most common of these 
medications specific to Sharp Hospice included: Atorvastatin, Metformin, Amlodipine, 
Metoprolol, and Hydralazine. Removal of target medications in the four weeks succeeding 
hospice admission is defined as appropriate deprescribing. 
In this project, patients were previously seeking complete medical treatment and, during a 
hospital admission, changed goals of care to comfort-focused hospice services. Although this 
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specific inclusion criteria reduced the sample size, it was necessary to view the medication lists 
before and after initiating hospice. The inclusion criteria were patients who initiated hospice 
services directly after an inpatient admission at a Sharp hospital from August 01, 2020, to 
August 31, 2020, or discharged patients of the palliative care physician from the affiliated 
medical group. Exclusion criteria were patients who were previously enrolled in the Sharp 
palliative care “Transitions” program as these patients had a previous medication review before 
their hospice enrollment. This specific group of participants would have skewed the data 
resulting in a misinterpretation of results as many medications would have been previously 
deprescribed while in the Transitions program. Sharp hospitals are located primarily in southern 
San Diego County, yet Northern County has providers who also refer patients to Sharp Hospice. 
This specific data was retrieved but excluded from analysis due to the inability to view outside 
medical records. If there were the ability to access the medications administration records 
(MARs), this would have increased the project’s sample size.  
Intervention  
Due to COVID-19 pandemic restrictions, the project's design required modification to a 
quality improvement rather than an interventional, evidence-based practice project. Originally 
the intervention was designed to target clinicians, including physicians and nurse practitioners, 
with evidence-based education for deprescribing but this approach was not permitted due to 
pandemic isolation restrictions. Instead, the project focused on the early phase of quality 
improvement – data collection and analysis to identify potential target goals for deprescribing. 
Identifying the eligibility of enrolled hospice patients provided valuable information regarding 
the scope of the problem and measured the gap in practice to set target goals for the program's 
next phase. 
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Measurable Outcomes 
The outcome measures are broken down into three major sections. The first section looks 
at the percent of target medications on the MAR while admitted to a Sharp facility. This initial 
measurable outcome set a baseline to determine the percentage of patients taking any of the 
target medications appropriate to be deprescribed immediately before hospice enrollment. Noting 
the percent of target medications remaining on the MAR at hospice admission is the second 
measurable outcome. This section of the data notes patients who are eligible for deprescribing 
target medications and capture how many are being deprescribed appropriately upon admission. 
Third, the percent of patients who still had the target medications on their MAR was noted four 
weeks after hospice admission. This data shows baseline deprescribing without any intervention 
to providers. In summary, the percentage of target medications at several time points was 
collected: before the hospice admission, after the hospice admission, and in the four consecutive 
weeks after hospice services have begun. This data is critical as it summarizes actual 
deprescribing rates and captures at what time point deprescribing was the highest in the sample. 
Data Collection   
Facilitators of this project included internal motivation and stakeholder support from 
Sharp Hospice, the ability to access the data, and a national deprescribing network providing 
specific guidelines. Barriers included data collection methods and organizational focus on the 
evolving pandemic. My clinical mentor retrieved data for the project to solve the limitation of 
students not being allowed on-site at Sharp Hospice. The second barrier included the 
organizational focus on patients and clinical support rather than initiating new projects. This 
resulted in a project design modification to prepare for implementation phases when Sharp 
Hospice can work on quality improvement projects. 
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All participants admitted between August 01-August 31, 2020, were included if they had 
any of the target medications prescribed and had been admitted into Sharp hospice from a Sharp 
facility. An individual chart review of each patient’s hospital discharge MAR was compared to 
the hospice admission medication list.  A second medication review was completed four weeks 
after admission to determine if and when the target medications were discontinued. Basic 
demographic data, including age, gender, race, religion, and primary language was collected to 
gather information on what barriers may be associated with deprescribing and relevant 
demographical information. If the age exceeded 90 years old, the age was recorded as “>89” to 
protect patient identity. Information regarding the location at the time of hospice referral, the 
hospice admission diagnosis, if discharged from the hospital with target medications, and 
specific target medications were recorded. Coding the subjects allowed for anonymous data 
collection, and no use personal identifiers were documented. 
Protection of Human Subjects 
Several organizations, including Sharp Hospice, Sharp Healthcare, and the University of 
San Diego, approved the project. The University of San Diego approved the project through the 
Institutional Review Board (IRB). After presenting the project methodology to the members of 
the Sharp Grossmont Hospital IRB team, Sharp Hospice's clinical director, vice president, and 
participating clinicians, it was approved. Privacy and confidentiality were protected by using a 
de-identified data set to analyze project outcomes. This data set will be kept for three years on a 
password-protected thumb drive, and results will be shared only in an aggregated manner. After 
three years, data will be destroyed. 
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Framework 
DMAIC Framework  
As an organization, Sharp healthcare utilizes LEAN Six Sigma for a systematic approach 
for continuous and successful improvement. DMAIC is the LEAN Six Sigma problem-solving 
approach and stands for “Define, Measure, Analyze, Improve, and Control”. Applying this 
framework allowed for a systematic approach for a quality improvement project. The first step of 
DMAIC is to understand the scope of the problem; this is the essential step as it lays a foundation 
for a well-defined project that is easier to manage and meet projected outcomes. During 
participation in the weekly Sharp Hospice interdisciplinary team (IDT) meetings, improvement 
opportunities were defined as a lack of standardization regarding deprescribing. Measuring the 
data was completed through individual chart reviews and analyzing the data to determine 
percentages of deprescribing at specific time intervals. There was a significant amount of high-
quality evidence on deprescribing of specific medications in the hospice population. Due to 
project modifications, a root cause analysis could not be completed as it became an early phase 
noninterventional QI activity. Therefore, the improvement and control phases of the process 
were not completed. Moving forward into the subsequent phases of this project, completing a 
root cause analysis will determine what barriers hinder deprescribing. This will allow for a pre-
and post-implementation data analysis to compare the volume of deprescribing. Lastly, the 
improvements should be sustainable and disseminated through Sharp Hospice providers and 
clinicians (Sharp: DMAIC, 2020). 
Change Acceleration Process Model   
The Change Acceleration Process Model is a set of tools to facilitate the acceleration of 
change through implementation within the organization. Sharp Healthcare uses CAP to assess 
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the climate before any change has begun and increase the possibilities of successful change that 
is sustainable and quick. Creating this project with the COVID-19 pandemic restrictions in mind, 
it became apparent the ability to change deprescribing processes in Sharp Hospice would remain 
incomplete. However, CAP was used to design the project methodology and work toward 
completing deprescribing protocols to implement effectively and efficiently. Changes to a 
medication regimen can be daunting for patients and their families, especially during a time of 
such rapid changes. Deprescribing, although found to have multiple benefits, should be done 
with patient and family-centered decision-making in healthcare delivery. This model is 
imperative to use for the successful data dissemination to Sharp Hospice providers, which 
directly translates to how well the improvement of deprescribing will be (Change Acceleration 
Processes (CAP), n.d.).  
Meleis’ Transitions Theory  
Meleis’ Transition theory (2000) serves as a template for the multitude of concepts 
regarding change as patient move through different care settings. In this model, Meleis and 
colleagues outline several vital areas one must first understand to create a change that is not only 
feasible but sustainable. Awareness, the first step in the transition model, is a defining 
characteristic of any change, which is similarly true regarding shifting goals of care from 
complete medical treatment to hospice services. With understanding and awareness of the 
circumstances and inevitable bodily failure, hospice changes can be welcomed with ease 
compared to impediment by utilizing Meleis’ Transition Theory. Deprescribing awareness is 
significant for patients’ and families’ positive support of the changes made to the medication list, 
and this is done so by engaging them in conversation throughout the hospice enrollment. 
Providing a simplified synthesis of the research supporting deprescribing and how beneficial it is 
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for their loved one is more likely to lead to medication changes and minimize hesitation 
regarding risk of deprescribing. Timespan is critical to recognize. Successful change does not 
occur rapidly; hence, collecting data to capture how many patients are deprescribed in the first 
month of hospice admission will provide information determining if change is readily accepted 
in the first four weeks. Meleis’ Transition Model serves as a guide to ease hesitation around 
deprescribing and create an achievable hospice transition for the patient and their family (Meleis 
et al., 2000). 
Holmes’ Model of Deprescribing  
After reviewing several existing frameworks and guidelines, Holmes determined a need 
for all providers to consider deprescribing at every patient interaction (2015). The Holmes’ 
Model of Deprescribing identified five recommendations for deprescribing in patients with 
limited life expectancy. The five recommendations include shared decision making, not 
prescribing medication as an option, deprescribing as a part of prescribing, embracing 
uncertainty, and the impact of difficult discussions. This model helps guide an understanding of 
how deprescribing is different with end-of-life patients and the unique challenges and associated 
barriers, which may be successfully overcome. (Todd & Holmes, 2015).  Using these 
recommendations in conjunction with the frameworks for successful change can lead to an 
effective implementation of deprescribing at Sharp Hospice. These recommendations add value 
to this phase of the project and benefit the application of intervention in the next phase.  
Results 
Data analysis revealed the percentage of deprescribing of target medications and allowed 
review of any missed opportunities for deprescribing. One hundred sixty-four patients were 
admitted to Sharp Hospice from August 01, 2020, to August 31, 2020. Of the total 164 patients, 
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60 were automatically excluded from the project as their referral source was an outside agency 
other than Sharp Healthcare, resulting in the inability to access the inpatient MAR. A second 
exclusion included whether death occurred during the initial four weeks after hospice enrollment, 
which equated to 40% of the patients. The final number of eligible patients was 34. 
The first outcome was the percentage of target medications on the MAR while the patient 
had a hospital stay in a Sharp facility, as shown in Figure1. There were three target medication 
classes, of which equaling 80.5% were antihypertensives, 61.1% were statins, and 22.2% were 
oral hypoglycemic medications. 
Figure 1 
Percentage of Target Medications Before Hospice Admission Eligible to Deprescribe  
 
It was noted 61.76% of patients were taking at least two of the target medications, and 
14.70% of patients were taking three or more of the target medications eligible for deprescribing. 
Deprescribing was evaluated in three ways: fully, partially, or not at all deprescribed. Fully 
80.50%
61.10%
22.20%
Antihypertensives
Statins
Oral Hypoglycemics
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deprescribed indicated discontinuation of all eligible medications from the MAR. Partially 
deprescribed indicated only some of the eligible medications were deprescribed and not 
deprescribed indicated no removal of the eligible medications.  
The second measurable outcome was to determine the percent of target medications 
remaining on the MAR at the hospice admission. 69.23% of patients were appropriately 
deprescribed at the time of hospice admission, 7.69% of patients were partially deprescribed, and 
23.08% of patients were not deprescribed as shown in Figure 2. The percentage of change from 
before hospice admission to directly after admission was a 64% difference in removing eligible 
target medications from the MAR.  
Figure 2  
Deprescribing at Different Intervals  
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The third outcome measured was the percent of target medications on the MAR at four 
weeks post hospice enrollment. Of these, 31.03% had all target medication deprescribed, 10.34% 
had some target medication remaining on the MAR, and 13.79% had all the target medication 
remaining on the MAR from pre hospice enrollment. One explanation for the decrease at the 
four-week time is patients who died before that measurement point. 
Analysis of the demographics revealed the mean age range was 77 years old; 61.7% were 
female, and 38% were male. The most prevalent race was Caucasian totaling 41.67%, and the 
second was Hispanic at 28.57 %. Interestingly, there was only one Arab-American patient, which 
may reflect the impact of culture, race, religion, and primary language spoken on hospice 
deprescribing. There were three primary hospice diagnoses, including congestive heart failure 
(10.34%), chronic obstructive pulmonary distress (10.34%), and cancers collectively (20.58%), 
as seen in Figure 3. 
Figure 3  
Hospice Admission Diagnoses 
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Cost Analysis 
Due to the project design and remote interactions, there were no costs associated with the 
early phase of this project. Data was collected from existing admission and census reports. 
Although the target medications were not a direct organizational cost of Sharp Hospice, 
reduction of polypharmacy and appropriate deprescribing can have a substantial financial impact 
on healthcare costs. Of the 34 patients included in this project, 61.1% of patients were taking a 
statin. As an exemplar, the median cost for a 30-day supply of Atorvastatin is $18.00 
(Atorvastatin Prices, Coupons & Patient Assistance Programs, 2021). Twenty-three patients were 
taking the medication multiplied by the monthly cost equaled to $414.00 per month (23 x $18.00 
= $414.00). A deprescribing protocol in place for this one medication alone could result in 
significant savings per month. Reducing out-of-pocket monthly medication costs is a significant 
facilitator for patients agreeing to deprescribing (Kutner, et al., 2015; Bukowy & Teso, n.d.) 
Strength and Limitations 
This project's strength was an accurate depiction of how deprescribing is done in Sharp 
Hospice, determining baseline percentages of deprescribing completed by the providers. This 
baseline data is valuable information for project continuation and the interventional 
implementation component. Due to the clinical site being inaccessible because of pandemic 
restrictions and necessary organizational priorities, the project required redesigning from 
interventional to an early-phase quality improvement project. The major limitation of this project 
was the inability to complete an intervention to increase deprescribing as the pandemic restricted 
physical contact with patients, families, and Sharp Hospice providers.  Another critical limitation 
to take into consideration was the small sample derived from only one hospice organization in a 
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limited time period which may not be an accurate representation of other hospices or a longer 
measurement period. 
Implications 
 The choice to deprescribe is not a simple decision; it is instead a complicated and open-
ended obligation requiring careful examination of the patient as a whole. The finding of this 
project’s early phase demonstrated appropriate deprescribing was completed yet found some 
medications eligible for discontinuation were not removed for undetermined reasons. The 
original PICOT question was unable to be unanswered, but this phase of the project allowed for a 
preliminary analysis of current deprescribing rates in Sharp Hospice. This information is 
valuable for understanding a baseline and plan for actions that will improve deprescribing in the 
subsequent implementation phase. For example, in the first four weeks of hospice enrollment, 
40% of the patients eligible for the project died although this is a non-modifiable excluding 
factor. When designing the next phase of implementation this group of patients could benefit 
from immediate deprescribing upon hospice enrollment compared to a delay in deprescribing, as 
seen in the four-week post-enrollment analysis. Without this pre-phase implementation project, it 
would have been challenging to create a meaningful and successful project to improve 
deprescribing. This phased implementation may provide insight to other hospice agencies 
reviewing deprescribing in their practice. The early phase allowed determination of a baseline 
deprescribing rate and clarified what medications are most common to the specific patient 
population of Sharp Hospice. This information would be beneficial to know before implementing 
a standardized deprescribing protocol in Sharp Hospice or elsewhere. The specificities may 
differ in other regions, resulting in a need for modification and individualization of other 
agencies' project planning.  
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Although hospice care primary objective is eliminating distress during the end-of-life 
period, polypharmacy may still occur, resulting in unwanted consequences for patients. Adverse 
drug events can be reduced or eliminated by accurately deprescribing when medically 
appropriate and necessary. A significant percentage of patients were taking at least two of the 
target medications. As mentioned earlier, there is a risk of adverse drug events occurring with 
medication combinations which can more readily induce the polypharmacy cascade. This 
analysis revealed that more than half of the organization’s new patients were eligible for 
deprescribing. Sucessful future implementation could be realized after designing a systematic 
organizational program for deprescribing using DMAIC. An essential step for the interventional 
phase would educate patients and their families to provide a comprehendible rationale. Meleis’ 
Transition Theory is also beneficial for application when providing education as it touches on the 
sensitive nature involved with changes and how barriers may be overcome (Meleis et al., 2000).  
Other implications to consider are the various factors that might influence the patient’s 
and family’s approval for a plan to deprescribe. Some medications were deprescribed during the 
hospice admission yet not fully. This could have resulted from multiple factors such as race, 
religion, and primary language spoken. Demographic factors have historically been associated 
with differences in patients’ preferences in medical care and may continue in similar attitudes for 
hospice care. Although demographic data was collected, it was beyond the scope of an 
evidenced-based practice project to determine an impact of demographics on deprescribing. 
Applying the Holmes Model of Deprescribing, a screen for patient’s willingness to accept 
education regarding deprescribing should be included in the next phase of implementation in the 
pre-implementation data collection process (Todd & Holmes, 2015). Unfortunately, it was not in 
the project’s scope to capture this data, as it is difficult and complex with many variables 
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influencing the patient’s decisions. In the next phase of interventional implementation, it would 
be valuable to understand how demographics create barriers or facilitate deprescribing.  
There are exceptions to deprescribing in the classes of target medications in this project, 
which is another important consideration. Of the 34 patients included, 80.5% of patients were 
receiving antihypertensive medications. Although noting different medication types in this class, 
all antihypertensives were grouped together for data collection feasibility due to the inability to 
conduct a thorough review of each patient’s chart, because of site access restrictions. For 
example, most antihypertensive medications observed in this project included: angiotensin 
converting enzyme (ACE) inhibitors, beta blockers, and calcium channel blockers. Although all 
medications in this class have a blood pressure lowering effect, beta blockers are used 
consistently for heart rate control (Mann, 2020). Beta blockers, such as Metoprolol and 
Carvedilol, should remain prescribed to prevent uncontrolled and chaotic heart rate fluctuations 
in patients with atrial fibrillation. A substantial percentage of patients, 38.2%, were taking one of 
these medications. Although classified initially as an eligible medication for deprescribing, when 
reviewed in depth removing the medication was determined to be not appropriate. This is a 
caveat for deprescribing antihypertensives, and the clinician must consider individual 
consideration of each patient before removing medications. These nuances and specific situations 
were not accurately captured in this project and would require a separate, more detailed patient 
record review and data collection process once organizational priorities have shifted from the 
ongoing pandemic.  
 Deprescribing is a safe way to reduce polypharmacy occurrences and continue to uphold 
the ethical principle of non-maleficence. DMAIC, the change acceleration process, and Holmes 
Model of Deprescribing require a thorough assessment of the current situation to implement a 
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successful project. Upon completion, several implications emerged, and these findings may be 
generalizable to other organizations as they are specific to the hospice population in general, not 
just Sharp Hospice. Although completing many of the project’s activities was not possible in this 
phase, it created an unwavering foundation to build the subsequent implementation phase. This 
early phase may serve as a reference for other hospice agencies to help guide a sucessful 
deprescribing project plan.  
Conclusion 
Successful deprescribing starts with understanding evidence-based recommendations and 
organizational baseline data. Although there are deprescribing protocols and guidelines, a 
standardized, fully implemented guideline for each target medication class would improve 
deprescribing rates. The findings from this project demonstrate the lack of deprescribing in the 
hospice population. Further understanding and increased education to the geriatric population 
(hospice and non-hospice) would help improve the knowledge regarding deprescribing safety 
and perhaps increase the percentage of patients willing to have medications removed. The topic 
of deprescribing is frequently disregarded as a part of a medical visit, yet it is just as important as 
prescribing itself. This project illustrated who in hospice was eligible for deprescribing, who was 
adequately deprescribed, and existing gaps for improvement. 
In conclusion, not every medication type could be deprescribed safely; it requires a 
skilled and experienced clinician to review each medication and determine continuation, dose 
reduction, or deprescription. Disseminating this baseline data to Sharp Hospice's clinicians and 
leaders for discussion and action planning will be included in the project's implementation phase. 
The next feasible step would be to assess and reduce the barriers hindering deprescribing and to 
create a meaningful program to reduce the burden of unnecessary medications for hospice 
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patients. Although not originally planned, this phased project established a foundation for higher 
impact intervention project in the future.   
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